Spirurida

• Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).
• The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases.
• After months of careful assessment, in July, WHO released a decision-making framework for resuming MDA during the ongoing pandemic.
• The SARS-CoV-2 pandemic is especially challenging for communities that continue to be threatened by river blindness and lymphatic filariasis.

Consumer Spending Levels on Dogs vs. Cats
Consumer Spending Levels on Dogs vs. Cats
PetIQ Expanding Petcare Clinic Locations at Walmart, Meijer
Parasiticide Use Impacted by Product Confusion, Perception of Risk
Usage Rates for Heartworm Prevention: Dogs vs. Cats

• Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today announced the U.S. approval of BRAVECTO PLUS topical solution for cats by the U.S. Food and Drug Administration (FDA).
• BRAVECTO PLUS is an extended-duration, broad-spectrum combination (fluralaner and moxidectin) topical solution for cats, indicated for both external and internal parasite infestations: ticks and fleas, heartworm, intestinal roundworm and hookworm.
• BRAVECTO Topical Solution for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy and scabs/ulcerated lesions.
• Neurologic abnormalities have been reported in cats receiving BRAVECTO, even in cats without a history of neurologic abnormalities.

• today announced that its scientists presented positive efficacy data for the companys investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La.
• Our data support the decision to use a 24 g/kg dose of moxidectin in our investigational combination product.
• As previously disclosed in its second quarter earnings, Zoetis combination parasiticide product is in regulatory review in the U.S., Canada, Brazil, Australia and Japan, as well as with the European Medicines Agency.
• The Companion Animal Parasite Council (CAPC) recommends annual heartworm testing and prevention of heartworm infection though the use of year round preventatives in all dogs (8).